share_log

Chardan Capital Reiterates Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target

Chardan Capital Reiterates Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target

查丹資本重申買入 Orchestra BioMed Holdgs,維持20美元的目標股價
Benzinga ·  2023/05/15 04:29

Chardan Capital analyst Keay Nakae reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.

Chardan Capital分析師Keay Nakae重申Orchestra BioMed Holdgs(納斯達克股票代碼:OBIO)的買入並維持20美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論